Skip to main content
Premium Trial:

Request an Annual Quote

Lucence, National Cancer Centre Singapore to Study Liquid Biopsy Assay in Prostate Cancer

NEW YORK – Precision oncology company Lucence said on Tuesday that it has entered into a research collaboration with the National Cancer Centre Singapore to evaluate the company's LiquidHallmark assay for improving prostate cancer treatment in Asian men.

The collaborators plan to conduct a prospective study to better define the clinical utility of LiquidHallmark in guiding treatment decisions and achieving therapy outcomes among men with metastatic castration-resistant prostate cancer.

The expanded LiquidHallmark next-generation sequencing assay measures both circulating tumor DNA (ctDNA) and RNA (ctRNA) in patients' blood.

While ctDNA is often used to determine disease presence and estimate tumor burden, Lucence plans to use ctRNA to highlight additional actionable targets.

"We believe that advancing cancer care needs both quick and comprehensive profiling to support clinical decisions, and combining ctDNA and ctRNA liquid biopsy will be an important part of that future," Min-Han Tan, Lucence's CEO, said in a statement.

The Scan

Germline-Targeting HIV Vaccine Shows Promise in Phase I Trial

A National Institutes of Health-led team reports in Science that a broadly neutralizing antibody HIV vaccine induced bnAb precursors in 97 percent of those given the vaccine.

Study Uncovers Genetic Mutation in Childhood Glaucoma

A study in the Journal of Clinical Investigation ties a heterozygous missense variant in thrombospondin 1 to childhood glaucoma.

Gene Co-Expression Database for Humans, Model Organisms Gets Update

GeneFriends has been updated to include gene and transcript co-expression networks based on RNA-seq data from 46,475 human and 34,322 mouse samples, a new paper in Nucleic Acids Research says.

New Study Investigates Genomics of Fanconi Anemia Repair Pathway in Cancer

A Rockefeller University team reports in Nature that FA repair deficiency leads to structural variants that can contribute to genomic instability.